Literature DB >> 27984643

Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.

Matko Kalac1,2, Jennifer K Lue1,2, Emily Lichtenstein1, Ithamar Turenne1, Celeste Rojas1, Jennifer E Amengual1, Ahmed Sawas1, Changchun Deng1, Markus Y Mapara3, Joseph M Connors4, John Kuruvilla5, Owen A O'Connor1.   

Abstract

Entities:  

Keywords:  Hodgkin lymphoma; antibody-drug conjugate; autologous stem cell transplant; monoclonal antibodies; refractory disease

Mesh：

Substances：

Year:  2016        PMID： 27984643     DOI： 10.1111/bjh.14449

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  5 in total

1.  Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.

Authors:  Ann S LaCasce; R Gregory Bociek; Ahmed Sawas; Paolo Caimi; Edward Agura; Jeffrey Matous; Stephen M Ansell; Howland E Crosswell; Miguel Islas-Ohlmayer; Caroline Behler; Eric Cheung; Andres Forero-Torres; Julie Vose; Owen A O'Connor; Neil Josephson; Yinghui Wang; Ranjana Advani
Journal:  Blood       Date:  2018-04-27       Impact factor: 22.113

2.  Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.

Authors:  Peter D Cole; Kathleen M McCarten; Qinglin Pei; Menachem Spira; Monika L Metzger; Richard A Drachtman; Terzah M Horton; Rizvan Bush; Susan M Blaney; Brenda J Weigel; Kara M Kelly
Journal:  Lancet Oncol       Date:  2018-08-16       Impact factor: 41.316

3.  Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma.

Authors:  M Picardi; R Della Pepa; C Giordano; N Pugliese; C Mortaruolo; F Trastulli; M G Rascato; I Cappuccio; M Raimondo; M Memoli; M Monteverde; M Mascolo; F Pane
Journal:  Blood Adv       Date:  2019-05-14

4.  Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies.

Authors:  Theodoros Karantanos; Ioannis Politikos; Vassiliki A Boussiotis
Journal:  Blood Lymphat Cancer       Date:  2017-05-09

Review 5.  Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin's Lymphoma: So Many Options, How to Choose?

Authors:  Radhika Takiar; Yasmin Karimi
Journal:  Cancers (Basel)       Date:  2022-07-20       Impact factor: 6.575
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.